Inficure Bio has developed a new mouse model, the N-IF model. Mice are used as model organisms for studying human biology due to the genetic and physiological conformity between mice and humans. N-IF mice are unique as they spontaneously develop pathological fibrosis, rather than it being induced. This pathological progress is therefore more natural and provides better and faster results.
UBI Company Quretech Bio has reached a milestone in its development.
Recently, the company took its first investment capital and a cunning business development partner – a local player in Västerbotten.
After a thorough selection process, Lipum AB has been granted SEK 22 million from the EU’s Horizon 2020-initiative. This is a great leap forward for researchers who want to better quality of life for children and adults with chronic inflammatory diseases.
Umeå region’s life science companies and Umeå Biotech Incubator (UBI) have generated great successes during recent years. One of the contributing factors is the unique process that has been developed during the three-year HIBA project.
The results from the evaluation of the highly competitive national call “Projects for Better Health” were announced on March 18th. Again, two UBI-related cases are among the 22 successful applicants who receive funding. The total sum granted is 20,5 million SEK.
One year following the world’s most widespread manifestation for science we are back at it. Together with 52 other national organisations and stakeholders we argue that evidence and research are a vital part of creating the society of tomorrow.
The ninth edition of Biotech Umeå’s annual partnering event was the first ever to fill up before deadline. Around 30 Swedish and European investors met with 13 startups and early cases. Two weeks after the event participants report an impressive turnout – on average they have retained at least five active leads per company.
The first ever edition of Meet Umeå Life Sceince gathered over 70 branch experts, entrepreneurs and researchers in Stockholm. This after-work networking mingle allowed startups to connect with experienced professionals with industrial expertise and business know-how. The aim was to match our promising ideas with the skills necessary to grow successfully.
As we enter 2018, we look back at a hectic, inspiring and successful year for the incubator-related community of life science companies in Umeå. We are experiencing a surge in incoming ideas, elevated interest from the industry and a stronger demand for the incubator facilities and labs.
The Umeå-derived invention has taken nine years to go from idea to approved product for sale. Pernilla Abrahamsson, the creator of OnZurf Probe, has successfully ushered her innovation all the way from that moment of serendipity to CE-approval – the final milestone before launch.
A new national call named “Projekt för Bättre Hälsa” opens today and is a joint innovation drive from the strategic national research programmes SweLife and MedTech4Health. Collaboration is mandatory – but each applicant can land up to one million SEK in funding if successful. SweLife offers hands-on support to make that happen for your team.
The Umeå-based life science incubator commonly known as UBI is growing in both projects, plans and people. The team is now searching for a service-minded laboratory technician that can help to develop the thriving life science community growing in and around the incubator at Tvistevägen 48.
Jennie Ekbeck has been the leading figure for life science in Umeå and northern Sweden since she took on the CEO-role for Umeå Biotech Incubator in 2013. She was named “Innovation Angel” by Veckans affärer and Vinnova in december 2015 and last year Umeå kommun handed her the Equal Opportunies prize. Now, her leadership is gaining attention as she is one of four nominees for the title “CEO of the year” in the Umeå region.
The UBI alumni Lipigon Pharmaceuticals announced yesterday that the startup has entered into a target validation research agreement with Munich-based antisense therapeutics company Secarna Pharmaceuticals. The goal is to co-develop a best-in-class drug for treatment of severe forms of dyslipidemia and related lipid disorder driven diseases.
Inficure Bio has signed an investment deal acquiring external venture capital for the first time. The new partners contribute with broad competence and funding – and within one year the goal is to become an established player on the international market for development of anti-inflammatory and antifibrotic drugs.
Eighteen meetings in two days. The team from Umeå reported a record interest in our portfolio of startups at the Nordic Life Science Days in Malmö 12-14th of September. Record participation, new location, world renowned key notes, displays, discussions and panels added to the success of the largest life science event of the year in Scandinavia.
17 out of 18 participating innovators recommend other researchers to work with Umeå Biotech Incubator. A recent interview study shows the cases appreciate being questioned, challenged and coached into really testing their ideas before proceeding.
The Umeå-based startup Biosolens has officially been assigned a national mission to introduce the digital tool Patient Voice™ in Sweden. The app allows people with chronic gastointestinal problems to report wellbeeing and health status continuously, and healthcare professionals can then personlize their treatment regimens faster.
1st of April 2019 the European Medicines Agency (EMA)will open in a new location outside the UK following Brexit. As of the 1st of August 2017, nineteen different cities in Europe are in the run to host the EMA. The Stockholm-Uppsala region is one of them, and the innovative climate and entrepreneurial vibe is considered a major strength in Sweden’s offer #ematosweden.
Another large EU-grant of no less than 6 million Euro has been awarded to an international team of scientists – among them a biotech startup in Umeå. The UBI-alumni AcureOmics have taken on the task of finding a cure for Batten disease together with the research consortium BATCure.